EUCTR2009-012935-13-HU进行中（未招募）不适用
A randomized, double-blind, placebo controlled, multi-centre phase IIb dose finding study to assess the effect on GERD symptoms, safety and tolerability during four weeks treatment with AZD3355 in doses 60 mg, 120 mg, 180 mg and 240 mg bid as add-on treatment to a PPI in patients with GERD that are partial responders to PPI treatment - n.a.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 650
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of informed consent prior to any study specific procedures
- •2. Male or female. Females of childbearing potential must be using a highly effective contraceptive method for at least the previous 3 months, see Section 5.1.1
- •3. Age 18-70 years, inclusive
- •4. Body Mass Index (BMI) 18.5 – 35.0 kg/m2, inclusive
- •5. Have at least 6 months history of GERD symptoms (need not to be consecutive)
- •6. Continuously treated during the last 4 weeks before enrolment with daily optimized unchanged PPI therapy with doses according to the country label, or regional where applicable, for any GERD indication. Patients with endoscopy verified reflux esophagitis (Los Angeles classification grade A-D) within the last 8 weeks must have completed the prescribed 8 weeks treatment with a PPI. An optimized PPI treatment is a treatment which according to the investigator judgment can not be further improved by changing brand or dosing of the PPI.
- •7. Have a PPI prescription with refills that cover the whole study period or instructions by a physician to use an over the counter (OTC) PPI in accordance with the labelling of their prescription counter-part
- •8. Able to read and write in the local language and use the e-diary device
- •9. To be eligible for the screening phase the patients must have reported in the RESQ-7 using 7 days recall of symptoms, a minimum of 3 days and a rating of at least moderate intensity on at least one of the following items; a burning feeling behind the breastbone or unpleasant movement of material upwards from the stomach. (An algorithm which is programmed in the e-diary device, will determine eligibility automatically).
- •10. To be eligible for randomization the patients must have recorded in the RESQ-eD on the last 7 days before randomization, a minimum of 3 days with a symptom intensity of at least moderate on either item, or any combination of both items (eg 1 day on one item and 2 days on the other); a burning feeling behind the breastbone or unpleasant movement of material upwards from the stomach. (An algorithm, which is programmed in the e-diary device, based on the e-diary recordings, will determine whether the patient fulfils the criteria).
- •11. An upper gastrointestinal endoscopy is required before randomization provided that:
- •- no endoscopy has been performed within the past 24 months
- •- the most recent endoscopy within 24 months demonstrated mucosal breaks in the esophagus
- •- no documented endoscopy report from the most recent endoscopy within 24 months is available to the investigator.
- •If the most recent available documented report from an upper endoscopy within the past 24 months confirms the absence of mucosal breaks then the patient does not need to undergo an endoscopy during this study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients that have not experienced any GERD symptom improvement at all during PPI treatment
- •2. PPI treatment with doses not according to the country label, or regional where applicable, for any GERD indication. Note: bid dosing is not allowed
- •3. Working night-shift during the period of the study
- •4. Unstable or clinically significant cardiovascular, respiratory, hepatic, renal, metabolic, psychiatric, other clinical disorders, or gastrointestinal and esophageal disorders besides GERD. Clinically significant is defined as disorders that could compromise patients’ safety or interfere with the evaluation of the study as judged by the investigator. Patients with uncomplicated, well-controlled hypertension (SBP=160 and DBP= 90) and patients with uncomplicated, well-controlled Diabetes Mellitus, as judged by the investigator, can be included
- •5. Current neurological disorders including nerve compression syndromes. Patients with well controlled migraine and other headache disorders can be included
- •6. History of clinically significant orthostatic reaction or syncope. Clinically significant orthostatic reaction at visit 1 or pre-dose at visit 2
- •7. Supine systolic blood pressure below 110 mm Hg at visit 1 and pre-dose visit 2
- •8. History of a heart disease (including ischemic heart disease, congestive heart failure, cardiac arrhythmias, congenital long QT syndrome), or current signs or symptoms of any heart disease, or patients with clinically significant ECG abnormalities or QTcF >450 ms as determined by the investigator (see section 6.4.7)
- •9. History of or current malignant disease (radically treated basal cell cancer is allowed)
- •10. History of clinically significant electrolyte imbalances
- •11. A history of severe allergic or hypersensitivity reactions (such as Stevens Johnson syndrome, anaphylactic shock, angioedema-urticaria)
- •12. Need for concomitant medication with:
- •· Drugs or any compound that may interfere with the pharmacodynamic effect of investigational product (eg, Baclofen, pure GABA, supplements containing GABA)
- •· Drugs that by their mode of actions may alter gastrointestinal (GI) symptoms, with exception of the PPI used in the study and antacids, (eg, H2 receptor antagonists, sucralfate, alginates, tegaserod, domperidone, metoclopramide, erythromycin), drugs with significant anticholinergic effect (eg, anticholinergics used in gastro-intestinal disorders; anticholinergics used for Parkinson’s disease; anticholinergics used for urine bladder disorders; tricyclic antidepressants)
- •· Drugs that may cause mucosal damage in the GI tract
- •- Non-steroid anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors, more than 2 days/week
- •- Acetylsalicylic acid (ASA) >162 mg/day
- •- Bisphosphonates
- •- Antineoplastic drugs
- •· Drugs that may prolong the QT interval. Common examples of such drugs are listed in Appendix E. This list should not be considered comprehensive therefore investigators need to use their judgement when reviewing the medication list from individual patients and restrict patients who must stay on drugs that may increase the QT interval
- •· Drugs that have a narrow therapeutic window (eg, warfarin, digoxin, phenytoin, carbamazepine)
- •13. Prior surgery of the upper GI tract (open, endoscopic and laparoscopic surgery on the esophagus, the stomach and the duodenum with the exception of oversewing or endoscopic treatment of a bleeding ulcer)
- •14. History of drug addiction, drug abuse (including cannabinoids) or alcoho
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of RO7123520 as Adjunct Treatment in Patients With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to TNF-a InhibitorsMedDRA version: 20.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2016-002126-36-ESF. Hoffmann-La Roche Ltd204
进行中（未招募）
1 期
Efficacy and safety study evaluating a new sublingual treatment in HDM allergic rhinitisHouse dust mite allergic rhinitisMedDRA version: 18.0Level: LLTClassification code 10001725Term: Allergic rhinitis due to other allergenSystem Organ Class: 100000004855EUCTR2014-004223-46-ESStallergenes S.A.990
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of Ritalin® LA in adult patients with childhood-onset ADHDAdult patients with childhood-onset Attention Deficit Hyperactivity DisorderMedDRA version: 12.1Level: LLTClassification code 10003735Term: Attention deficit-hyperactivity disorderMedDRA version: 12.1Level: LLTClassification code 10003736Term: Attention deficit/hyperactivity disorderMedDRA version: 12.1Level: LLTClassification code 10003737Term: Attention deficit/hyperactivity disorder NOSMedDRA version: 12.1Level: PTClassification code 10003736Term: Attention deficit/hyperactivity disorderEUCTR2010-021533-31-DKovartis Pharma Services AG700
进行中（未招募）
1 期
Safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyDiabetic nephropathyMedDRA version: 16.1 Level: PT Classification code 10061835 Term: Diabetic nephropathy System Organ Class: 10038359 - Renal and urinary disordersEUCTR2012-004179-38-NLBayer HealthCare AG823
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of Obinutuzumab, an antibody targeting certain types of immune cells, in Patients with Lupus NephritisEUCTR2015-002022-39-FRF. Hoffmann-La Roche Ltd125